ELIAS JOSEPH JABBOUR to Drug Therapy, Combination
This is a "connection" page, showing publications ELIAS JOSEPH JABBOUR has written about Drug Therapy, Combination.
Connection Strength
0.488
-
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.
Score: 0.103
-
Deacetylase inhibitors for the treatment of myelodysplastic syndromes. Leuk Lymphoma. 2015 May; 56(5):1205-12.
Score: 0.085
-
Clofarabine in the treatment of myelodysplastic syndromes. Expert Opin Investig Drugs. 2014 Feb; 23(2):255-63.
Score: 0.079
-
Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood. 2011 Jul 28; 118(4):899-902.
Score: 0.065
-
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021 06; 11(6):1440-1453.
Score: 0.032
-
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018 11 01; 124(21):4192-4201.
Score: 0.027
-
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017 Dec 15; 123(24):4851-4859.
Score: 0.025
-
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res. 2014 Sep; 38(9):1126-9.
Score: 0.020
-
Sustained virologic response after 6 weeks of therapy with a first-generation hepatitis C virus protease inhibitor. Clin Infect Dis. 2014 May; 58(9):1342-4.
Score: 0.020
-
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012 May; 157(3):312-20.
Score: 0.017
-
Clofarabine in leukemia. Expert Rev Hematol. 2010 Feb; 3(1):15-22.
Score: 0.015